[CAR-T therapy for autoimmune diseases].

Cellular therapy using genetically modified T lymphocytes expressing synthetic receptors, known as CAR (Chimeric Antigen Receptor), has revolutionized the treatment of certain hematologic malignancies. This success has led to exploring the same approach in the treatment of severe autoimmune diseases refractory to conventional therapies. Initial results in systemic lupus erythematosus have shown complete remissions that appear to persist over time. Consequently, there is a growing number of ongoing clinical trials. In this review, we discuss the rationale behind the use of CAR-T therapies, the targeted autoimmune diseases, and the associated risks.
Competing Interests: Le Pr Y. D. Müller est inventeur d’une licence sur les CAR-T (US 2023/0340068 A1) et responsable de site d’une étude CAR-T (NCT05798117). Les autres auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.